marked.bio

Company

Convalife

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

sacituzumab tirumotecan 1trastuzumab deruxtecan 1enfortumab vedotin 1

Trials

2 of 3 trials shown

  1. CVL006 Combination Therapy in Advanced Solid Tumors

    Not yet recruiting Phase 1/2 Convalife Started 2025Primary completion 2028-08 NCT07157956

    pemetrexedcarboplatinsacituzumab tirumotecantrastuzumab deruxtecanenfortumab vedotin

    …rm2.1, Arm2.2, Arm2.5 and Arm2.7: For NSCLC Arm2.1: Non-squamous, wild-type NSCLC Arm2.2: EGFRm nsqNSCLC Arm2.3: Malignant pleural mesothelioma Arm2.4: triple-negative breast cancer Arm…

    EGFR exon 19 deletion / L858RAdvanced Solid Tumor

  2. Clinical Study of CVL006 Injection in Advanced Solid Tumors

    Not yet recruiting Phase 1 Convalife Started 2024Primary completion 2028-05 NCT06621615

    CVL006 Injection

    Queue 2: Malignant Solid Tumors of MSI-H/dMMR Subjects with locally advanced, recurrent, or metastatic MSI-H/dMMR malignant solid …

    MSI-H / dMMRStatus may be outdated, last updated 2024-10-01Advanced Solid Tumor